## Kimiteru Ito

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7614998/publications.pdf

Version: 2024-02-01

8 papers	235 citations	1937685 4 h-index	8 g-index
9	9	9	358
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography. Pharmaceutics, 2022, 14, 67.	4.5	3
2	Usefulness of semi-automatic harmonization strategy of standardized uptake values for multicenter PET studies. Scientific Reports, 2021, 11, 8517.	3.3	13
3	18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. Annals of Nuclear Medicine, 2021, 35, 1253-1263.	2.2	5
4	Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates. Pharmaceuticals, 2021, 14, 950.	3.8	4
5	Diagnostic Value of Model-Based Iterative Reconstruction Combined with a Metal Artifact Reduction Algorithm during CT of the Oral Cavity. American Journal of Neuroradiology, 2020, 41, 2132-2138.	2.4	9
6	<sup>18</sup> F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of Nuclear Medicine, 2019, 60, 335-341.	5.0	123
7	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 930-939.	6.4	75
8	Interim PET Evaluation By Deauville Criteria Is an Effective Risk Stratification Tool in PTCL. Blood, 2016, 128, 186-186.	1.4	3